Clin Cancer Res: Anti-ICAM1 antibody-drug coupled for potential activity of multiple myeloma.

The new treatment has changed the outlook for patients with multiple myeloma (MM), but new drugs need to be developed for patients who are difficult to treat or who relapse after treatment with currently approved medications.
with the emergence of resistance to Daremu monoantigen and emerging anti-BCMA methods, we need new targets other than CD38 and BCMA to develop new immunotherapies.
ICAM1 is a potential target for myeloma.
naked anti-ICAM1 antibodies are active in preclinical models of myeloma and are safe, but have limited clinical efficacy.
recently published in clinical Cancer Research, "Potent activityy of an anti-ICAM1 antibody-drug conjugatest multiple myeloma" article, researchers tried to improve the targeting of anti-ICAM1 antibodies to multiple myeloma by anti-ICAM1 antibody-drug conjugate.
researchers linked anti-ICAM1 monoclonal antibodies to Raoxitin derivatives and tested them in a variety of multiple myeloma cell line, in-place transplant models, and patient samples.
, ICAM1 expression levels were detected from diagnosis to patients with remnants of the disease through quantitative flow cytometics.
anti-ICAM1 antibody-drug couple have shown strong anti-myeloma cytotoxicity both inside and outside the body.
, the researchers found that ICAM1 was highly expressed in myeloma cells, and that the presence of myeloma microenvironment factors further enhanced its expression.
in primary samples, ICAM1 had differential over-expression in multiple myeloma cells compared to normal cells, including patients with a reduced CD38 daremu monoresponsive resistance.
, ICAM1-ADC exhibited selective toxicity to the original sample of multiple myeloma.
based on the above findings, Sherbenou et al. recommend that the toxicity, safety and clinical efficacy of anti-ICAM1 antibody-drug couples should be further evaluated in patients with relapsed or refrmmune multiple myeloma.
.